Replies to post #125636 on Biotech Values

[genisi]

The company also plans to rely less on patents and more on trade secrets. Because it has done so much more testing than anyone else, Myriad has more information on which of the thousands of possible mutations in the two genes actually raise the risk of getting cancer.

Sounds very logical. There could be many differences in the expressed genes due to the different mutations and therefore many phenotypes (degrees of activity of the proteins). If you monitor the patients long enough you get more insight from the statistics. The numbers do count.